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Abstract
The direct estimation of heritability from genome-wide common variant data as implemented in the program Genome-wide
Complex Trait Analysis (GCTA) has provided a means to quantify heritability attributable to all interrogated variants. We
have quantified the variance in liability to disease explained by all SNPs for two phenotypically-related neurobehavioral
disorders, obsessive-compulsive disorder (OCD) and Tourette Syndrome (TS), using GCTA. Our analysis yielded a heritability
point estimate of 0.58 (se = 0.09, p = 5.64e-12) for TS, and 0.37 (se = 0.07, p = 1.5e-07) for OCD. In addition, we conducted
multiple genomic partitioning analyses to identify genomic elements that concentrate this heritability. We examined
genomic architectures of TS and OCD by chromosome, MAF bin, and functional annotations. In addition, we assessed
heritability for early onset and adult onset OCD. Among other notable results, we found that SNPs with a minor allele
frequency of less than 5% accounted for 21% of the TS heritability and 0% of the OCD heritability. Additionally, we identified
a significant contribution to TS and OCD heritability by variants significantly associated with gene expression in two regions
of the brain (parietal cortex and cerebellum) for which we had available expression quantitative trait loci (eQTLs). Finally we
analyzed the genetic correlation between TS and OCD, revealing a genetic correlation of 0.41 (se = 0.15, p = 0.002). These
results are very close to previous heritability estimates for TS and OCD based on twin and family studies, suggesting that
very little, if any, heritability is truly missing (i.e., unassayed) from TS and OCD GWAS studies of common variation. The
results also indicate that there is some genetic overlap between these two phenotypically-related neuropsychiatric
disorders, but suggest that the two disorders have distinct genetic architectures.
Genetic Architecture of TS and OCD
PLOS Genetics | www.plosgenetics.org 2 October 2013 | Volume 9 | Issue 10 | e1003864
Citation: Davis LK, Yu D, Keenan CL, Gamazon ER, Konkashbaev AI, et al. (2013) Partitioning the Heritability of Tourette Syndrome and Obsessive Compulsive
Disorder Reveals Differences in Genetic Architecture. PLoS Genet 9(10): e1003864. doi:10.1371/journal.pgen.1003864
Editor: Matthew C. Keller, University of Colorado Boulder, United States of America
Received April 2, 2013; Accepted August 21, 2013; Published October 24, 2013
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This work was supported by a grant from the Judah Foundation, NIH grant NS40024 to DLP/JMS and the Tourette Syndrome Association International
Consortium for Genetics (TSAICG), NIH grant NS16648, MH079489, and MH073250 to DLP, NIH grant NS037484 to NBF, NIH grant 1R01MH079487-01A1 to JTM, New
Jersey Center for Tourette Syndrome and Associated Disorders and NIMH (R01MH092293) to GAH/RAK/JAT, NIH grant K20 MH01065 and R01 MH58376 and a grant
from the Obsessive Compulsive Foundation to GLH, Ontario Mental Health Foundation grant to PR and JLK, and a grant from the Tourette Syndrome Association and
NIH grant MH085057 to JMS, MH079494 to JAK and the OCD Collaborative Genetics Association Study which supported the imputation, by an American Academy of
Child and Adolescent Psychiatry (AACAP) Early Investigator Research Grant, an Anxiety Disorders Association of America (ADAA) Junior Investigator Research Grant, the
University of British Columbia and a Michael Smith Foundation Clinical Research Scholar Award to SES, and American Recovery and Re-investment Act (ARRA) awards
NS40024-07S1 to DLP/JMS and NS16648-29S1 to DLP. Additional support for analysis was provided by R01 MH090937 and P50MH094267 awarded to NJC. Support
was also provided by the Australian Research Council FT0991360 (NRW), DE130100614 (SHL) and the Australian National Health andMedical Research Council:1047956
(NRW), 1052684 (JY), and the German Research Foundation (DFG GR 1912/1-1) to HJG and to PF, SR, MW. Funding support for the Study of Addiction: Genetics and
Environment (SAGE) was provided through the NIH Genes, Environment and Health Initiative [GEI] (U01 HG004422). SAGE is one of the genome-wide association
studies funded as part of the Gene Environment Association Studies (GENEVA) under GEI. Assistance with phenotype harmonization and genotype cleaning, as well as
with general study coordination, was provided by the GENEVA Coordinating Center (U01 HG004446). Assistance with data cleaning was provided by the National
Center for Biotechnology Information. Support for collection of datasets and samples was provided by the Collaborative Study on the Genetics of Alcoholism (COGA;
U10 AA008401), the Collaborative Genetic Study of Nicotine Dependence (COGEND; P01 CA089392), and the Family Study of Cocaine Dependence (FSCD; R01
DA013423), and R01-MH-50214 (GN). Funding support for genotyping, which was performed at the Johns Hopkins University Center for Inherited Disease Research,
was provided by the NIH GEI (U01HG004438), the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse, and the NIH contract
‘‘High throughput genotyping for studying the genetic contributions to human disease’’ (HHSN268200782096C). The datasets used for the analyses described in this
manuscript were obtained from dbGaP at http://www.ncbi.nlm.nih.gov/projects/gap/cgibin/study.cgi?study_id=phs000092.v1.p1 through dbGaP accession number
phs000092.v1.p. None of the funding agencies for this project (NINDS, NIMH, the Tourette Syndrome Association and the Judah Foundation) had any influence or
played any role in a) the design or conduct of the study; b) management, analysis or interpretation of the data; c) preparation, review or approval of the manuscript.
Competing Interests: The following authors have read the journal’s policy and have the following conflicts: CLBu: Currently receiving funding for TS clinical trials from
Otsuka Pharmaceutical, JFL: recevies research support from NIH and Grifols, LLC as well royalties from John Wiley and Sons, McGraw Hill, and Oxford University Press,
MARic: received honoraria from Lundbeck, and research funding from Great-West Life Assurance Company of Canada and Eli Lilly Canada Ltd, MCR: grant from CNPq
(Brazilian National Counsil) and has received research grants and/or consultancy honoraria from Novartis and Shire, DR: received consulting fees for Shire, JMS: received
research support, honoraria and travel support from the Tourette Syndrome Association (TSA), DJS: received research grants and/or consultancy honoraria from Abbott,
Astrazeneca, Biocodex, Eli-Lilly, GlaxoSmithKline, Jazz Pharmaceuticals, Johnson & Johnson, Lundbeck, Orion, Pfizer, Pharmacia, Roche, Servier, Solvay, Sumitomo,
Takeda, Tikvah, and Wyeth, TVF: received research funding from NIMH (K08 MH099424-01), the Simons Foundation, Allison Foundation, and Shire, PS: received research
support for this study from the Tourette Syndrome Association (TSA), Tourette Syndrome Foundation of Canada and NIH, DY: received research support from the
Tourette Syndrome Association (TSA) and NIH, MMR: received grants from the Tourette’s Action-UK, TSA-USA, honoraria from Janssen-Cilag, and book royalties from
Wiley - Blackwell, David Fulton/Granada/Taylor Francis, Oxford University Press and Jessica Kingsley Publishers, is a Patron of Tourette’s Action (UK), sits on the Medical
Advisory Board of the Italian Tourette Syndrome Association and The Tourette Syndrome Foundation of Canada, DAC: NIH/NIMH funding for K01 MH072952 and R34
MH090149, SLR: participated in research funded by Medtronic and Cyberonics, JRW: Past employee of F. Hoffmann-La Roche and current employee of Pfizer, SW:
received lecture honoraria from Janssen Cilag, AstraZeneca and Eli Lilly, research funds Swiss National Science Foundation (SNF), Deutsche Forschungsgemeinschaft, EU
FP7, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, JV: funding from Seaside Therapeutics, Novartis, Roche Pharmaceuticals, Forest, and SynapDx.
Consulting/Advisory Board for Novartis, JTM: Tourette Syndrome Association-Speaker honoraria; Otuska-research grant; Roche-consultant; 1R01MH079487-01A1, JLK:
honoraria from Roche, Eli Lilly, and Novartis, PDA: Unrestricted research grant from DNA Genotek SLG,HJG,ML,DLP,SES,NL,JHS,CLBa,LB,FB,GBB,
OJB,MHB,RMB,RDB,DC,CC,JCCS,DCC,MCC,SC,DVC,EHC,VC,NJC,BAC,LKD,DDen,DDef,RD,EMD,YD,CKE,KE,PF,NBF,PJG,ERG,HG,MAG,BDG,VGT,SH,GLH,GAH,SMJH,PH,AGH,CI,JJ,MAJ,
CLK,RAK,JAK,AIK,BK,RK,SHL,LL,CLi,CLo,TLL,FM,CAM,LMM,WM,SCMR,ECM,RM,JM,HM,DLM,ALN,BMN,GN,HN,WCO,BAO,RAO,LO,AJP,MTP,CNP,CP,YP,DP,TJR,VIR,MARid,GAR,SR,ARL,
ASS,JS,BS,HSS,ES,JAT,AVVD,HV,MW,YW,JY,HGMW,PE,BC, RR have declared that no competing interests exist.
* E-mail: lea.k.davis@gmail.com (LKD); jscharf@partners.org (JMS)
. These authors contributed equally to this work.
{ Deceased
Introduction
For most complex traits, DNA sequence variants that meet the
genome-wide significance threshold do not explain the majority of
the heritability as estimated by twin and family studies [1].
Heritability (broad sense) is defined as the proportion of
phenotypic variance accounted for by genotypic variance within
a population. Narrow sense heritability is a special case of broad
sense heritability and refers to the proportion of phenotypic
variance that is due only to additive genetic effects. The limited
heritability explained by significant GWAS findings has led to the
so-called ‘‘missing heritability’’ dilemma and subsequent hypoth-
eses have been generated for how to capture the heritable factors
contributing to human trait variation [2], [3]. However, others
have argued that the proportion of heritability explained by ‘‘top
GWAS hits’’ is limited by currently available sample sizes and
analytic approaches, and that sub-threshold GWAS signals may
capture a much larger proportion of heritability [1], [4]. Indeed,
under current experimental conditions, genome-wide significant
GWAS findings alone are likely to account for a very small
proportion of total risk variants for many complex disorders and
by extension a small proportion of heritability.
Author Summary
Family and twin studies have shown that genetic risk factors
are important in the development of Tourette Syndrome
(TS) and obsessive compulsive disorder (OCD). However,
efforts to identify the individual genetic risk factors involved
in these two neuropsychiatric disorders have been largely
unsuccessful. One possible explanation for this is that many
genetic variations scattered throughout the genome each
contribute a small amount to the overall risk. For TS and
OCD, the genetic architecture (characterized by the num-
ber, frequency, and distribution of genetic risk factors) is
presently unknown. This study examined the genetic
architecture of TS and OCD in a variety of ways. We found
that rare genetic changes account for more genetic risk in
TS than in OCD; certain chromosomes contribute to OCD
risk more than others; and variants that influence the level
of genes expressed in two regions of the brain can account
for a significant amount of risk for both TS and OCD. Results
from this study might help in determining where, and what
kind of variants are individual risk factors for TS and OCD
and where they might be located in the human genome.
Genetic Architecture of TS and OCD
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The application of genome-wide estimation of heritability using
restricted maximum likelihood (REML) methods has provided a
new means to quantify narrow sense heritability attributable to all
interrogated variants in GWAS [5]. This approach, as imple-
mented in the Genome-wide Complex Trait Analysis (GCTA)
package, has been utilized to study a number of complex human
phenotypes including autism, schizophrenia, height, Parkinson’s
disease, type 2 diabetes, and hypertension, and has shown that a
significant proportion of genetic risk undiscovered by GWAS was
nevertheless detectable by REML heritability approaches [5], [6],
[7], [8].
Tourette Syndrome (TS) and obsessive-compulsive disorder
(OCD) are neurodevelopmental disorders with overlapping neural
circuitries and similarities in phenotypic expression [9], [10], [11].
Neuroimaging studies have implicated specific brain regions, i.e.
the ventromedial prefrontal cortex (VMPFC), anterior cingulate
cortex (ACC), orbitofrontal cortex (OFC), parietal cortex and
somatosensory cortex, along with the striatum and the thalamus,
as being involved in the pathophysiology of both OCD and TS
[12]. These brain regions are interconnected in multiple recurrent
loops, making up the cortico-striatal-thalamo-cortical (CSTC)
circuitry, and are thought to be involved in action selection,
performance monitoring, response inhibition, and goal-directed
behaviors [13], [14]. Both TS and OCD have a strong familial
component, and often co-occur within families. Multiple studies
have suggested that OCD and TS are both highly heritable
(h2 = 27%–45% adult onset OCD; 65% for childhood onset OCD,
h2 = 60% for TS) and likely to be genetically related [15–18], [19],
[20], [21,22], [23–25], [26], [27], [28], [29]. For review of TS
heritability studies see Scharf and Pauls, 2007.
This study sought to quantify the heritability of both TS and
OCD using genome wide genotype data and the REML approach
implemented in GCTA [5]. Here we present results from a
comprehensive heritability study of these disorders using thorough
and stringent quality controls. In addition to obtaining a direct
genetic estimate of total heritability for each trait, we also
examined the genetic architectures of TS and OCD by
partitioning genetic variation according to minor allele frequency,
chromosome, and functional annotation. Functional annotations
included annotation by genic regions as well as annotation of SNPs
correlated with gene expression in parietal cortex and cerebellum,
two brain regions for which we had previously generated eQTL
data. In addition, we assessed heritability for early onset and adult
onset OCD. Lastly, we conducted a bivariate analysis to examine
the genetic correlation between OCD and TS.
Methods
Ethics Statement
All participants 18 years of age and older gave informed
consent. Individuals under 18 years of age gave assent after a
parent signed a consent form on their behalf. The Ethics
Committees of each participating site approved this research and
the research was conducted in accordance with the Declaration of
Helsinki.
Sample
The datasets used in this study are described in depth elsewhere
[30,31]. Briefly, DNA from individuals with TS or OCD and from
controls was randomized across plates and genotyped using the
Illumina Human610-Quad genotyping array. Additional un-
screened controls that were genotyped as a part of the SAGE
(genotyped on Illumina HumanHap1Mv1_C) and iControl
(genotyped on Illumina HumanHap550v1/v3) datasets were also
included in this study. To reduce effects of population stratifica-
tion, subjects were limited to those with genetically defined
European ancestry, based on principal components clustering
analysis using genome-wide pairwise identity-by-descent (IBD)
information as estimated with EIGENSTRAT 3.0 [32] and
including previously defined European population samples as
reference (HapMap3.0).
Quality Control
The first phase of quality control analyses, including assessment
of Hardy-Weinberg equilibrium, differential missingness, platform
effects, population stratification, and genotyping call rate, was
conducted as a part of the recently published GWAS of OCD and
TS [30,31]. The variance components models in the REML
analysis utilized all unpruned genotype data simultaneously.
Because all genotypes are fitted together in a given variance
component, these components are particularly susceptible to
minor technical and experimental artifacts that might only
modestly affect each genotype (i.e., in a SNP-by-SNP test of
association) but could have a substantial cumulative global effect
on the results from a mixed linear model. We thus undertook
additional, more stringent quality control measures to minimize
any possible persistent population stratification and experimental
bias. Prior to case-control comparisons, we first focused solely on
the control dataset to develop our QC pipeline. We split the
controls by data source (iControl vs. SAGE controls) and
performed the following QC steps using PLINK. We implemented
stringent thresholds and removed additional SNPs showing low
levels of differential missingness between cases and controls
(p,0.05), modest deviation from Hardy-Weinberg expectation
(p,0.05), and significant platform effect after adjustment for all
ten principal components (p,0.001). In addition, individuals with
genotype call rate ,99.9%, or with a high degree of relatedness
(pi-hat.0.05) were removed (Table S1). To assess any residual
cross-platform artifacts that might artificially elevate the heritabil-
ity estimate, we conducted a dummy case-control GWAS by
assigning case status to the iControl data (N= 1,104) and control
status to the SAGE Controls (N= 2,190). We detected no
significant association with platform ‘‘phenotype’’ by logistic
regression (Figure S1) or ‘‘heritability’’ between cross-platform
controls (h2 = 1026, se = 0.11) (Table S2). Additionally, we
analyzed ten permutations of the dummy case phenotype and
detected no significant heritability in any permuted analysis. In
addition to these QC steps, we examined the data for any possible
residual population stratification or cryptic relatedness, which is
described in depth in the Supplementary Methods (Figures S1,
S2, S3, S4). The quality control and matching steps resulted in a
final data set of 617 TS cases and 4,116 TS controls genotyped on
393,387 SNPs, as well as 1,061 OCD cases and 4,236 OCD
controls genotyped on 373,846 SNPs. Each analysis included the
top 20 principal components as covariates.
Heritability Analysis
For each analysis presented, GCTA v1.2 ([5]; www.
complextraitgenomics.com) was used to create a genetic relation-
ship matrix (GRM) file containing IBD relationship calculations
for all pair-wise sets of individuals. Principal components were
determined within GCTA, using all genotype data, and the top 20
principal components were applied to each analysis. The REML
analysis was then performed using the respective GRMs and
principal component quantitative covariates. As this analysis was
performed with dichotomous case/control traits, it was necessary
to convert the phenotypic variance to an underlying liability scale.
This conversion uses population prevalence to adjust for case/
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control ascertainment in the sample and to modify the phenotypic
variance estimate accordingly [4]. We conducted primary analyses
using 2.5% for OCD prevalence and 0.8% for TS. As a range of
prevalence estimates for both OCD and TS are frequently
reported, we conducted additional sensitivity analyses to examine
the heritability estimates for TS and OCD across a range of
reported prevalences (Table S3) [33], [34], [35], [36]. Addition-
ally, we provide heritability results converted to the sibling relative
risk scale for further interpretation (Table S4). We conducted
three primary analyses (univariate TS heritability, univariate OCD
heritability, joint OCD and TS bivariate analysis) and five
exploratory analyses (partitioning by chromosome, MAF, genic
annotation, brain eQTL annotation, age of onset). For each
primary analysis, ten permutations of the phenotype were
performed and GCTA was run on each permutation to observe
the stability of the heritability estimate.
Bivariate OCD and TS Analysis
In addition, we calculated the genetic correlation between OCD
and TS using the GCTA bivariate REML analysis. We split the
shared control sample between the TS cases and the OCD cases in
a manner that preserved the matched ancestry structure and the
proportion of cases to controls for each disorder. An initial analysis
included co-morbid TS and OCD cases assigned to either the TS
or OCD samples based on their primary diagnosis as determined
by the clinical team. We conducted a secondary bivariate analysis
limiting the SNPs included to a subset of SNPs previously
identified as regulators of gene expression in the brain. A final
sensitivity analysis was conducted after removing all 316 case
samples with known overlapping comorbidity (83 OCD samples
with TS or chronic tics, and 233 TS samples with OCD) to assess
the effect of co-morbidity on the cross-disorder genetic correlation.
We then applied a likelihood ratio test (LRT) to determine the
statistical significance of each genetic correlation.
Imputation Analysis
Imputation was performed using IMPUTE v2.1.2 and the 1000
Genomes Project data as a reference panel. Only imputed SNPs
that were in strong linkage disequilibrium (LD) (info.0.6) with
genotyped SNPs and had a high certainty (.90%) of the predicted
genotypes were retained. Imputed SNPs that showed significant
genotyping platform effects were excluded. Imputed results were
converted to MaCH format (i.e., .mldose, .mlinfo) using an in-
house script. MaCH dosage data was used to create GRMs for
each chromosome. Chromosome specific GRMs were then
merged as needed for additional analyses. The total number of
imputed SNPs after QC included 7,657,106 SNPs in both the TS
and OCD samples.
Partitioning Heritability
By chromosome. A separate GRM was generated for each
chromosome. Each GRM was then run in separate REML
analysis. An additional analysis was conducted in which all
chromosomes were modeled jointly in a single REML analysis.
By minor allele frequency. We chose not to employ a
minor allele frequency (MAF) cutoff in any of the heritability
analyses. This decision was based on the observation that minor
allele frequency cutoffs did not alter estimates of heritability for the
control-control analysis after establishment of stringent differential
missingness rates and call rate. We partitioned the directly
genotyped and imputed variants according to MAF bin. For the
directly genotyped variants we created six bins representing MAFs
from 0.001–.05, .0.05–0.1, ..1–.2, ..2–.3, ..3–.4, and ..4–.5
and generated GRMs for each bin. For the imputed genotypes we
created two bins representing MAF 0.001–0.05 and .0.05 to 0.5
and generated GRMs for each bin. For each set of variants
(directly genotyped and imputed respectively) we then combined
binned GRMs in a single joint REML analysis, allowing the effects
of LD to be partitioned by the REML analytic approach.
By functional annotation. We annotated variants for genic
and intergenic classification using ANNOVAR (hg18, refGene)
[37]. Genic variants included all those variants annotated to exons,
introns, UTRs and splice sites. Intergenic variants included those
not otherwise annotated as genic. Additionally, we annotated
directly genotyped and imputed SNPs that we had previously
identified as significantly associated with gene expression
(p,0.001) in parietal cortex, (GSE35977), cerebellum
(GSE35974), and skeletal muscle (GSE40234). Details of the
eQTL detection are described in supplementary methods and in
previous publications [38–45]. Three sets of analyses were
conducted using the eQTL annotations. The first analysis simply
partitioned the parietal eQTLs and cerebellar eQTLs from their
respective complements for all imputed SNPs. The second model
included four partitions: 1) brain only eQTLs (those found in
cerebellum or parietal tissues but not in muscle), 2) muscle only
eQTLs (those found in muscle and not in either brain tissue), 3)
eQTLs common to brain and muscle, and 4) a final partition with
non-eQTL SNPs. The last analysis included four total partitions to
accommodate eQTLs exclusive to each brain tissue (cerebellum
and parietal) as well as eQTLs found in both brain tissues, and the
remainder of all imputed SNPs. Annotations were applied to the
TS and OCD case/control data and used to create partitions. This
resulted in a total of four separate annotation-based REML
analyses. For each analysis, we created a single GRM for each
partition. Finally, for each analysis, we included the functional
variant GRM(s) and the respective complement GRM together in
one joint REML analysis.
Age of onset subset (OCD). Multiple studies have reported
significantly higher heritability for early-onset OCD than for adult
onset OCD [16], [46]. Hanna and colleagues (2005) [47]
suggested a possible threshold of 14 years to define early-onset
OCD, however, as our data was collected retrospectively,
potentially introducing a recall bias, we chose to employ a
conservative threshold for early-onset of symptoms or diagnosis at
age 16. We sought to test the hypothesis that early-onset OCD is
more highly heritable than adult-onset OCD by dividing the OCD
sample based on symptom onset or age at diagnosis (#16= early
onset, .16= adult-onset). A total of 732 cases were diagnosed or
reported symptom onset prior to age 16 and were considered early
onset. A total of 267 cases were diagnosed or exhibited symptoms
later than age 16 and were classified as adult onset. Age of onset
data was missing for 62 cases. GCTA analysis was performed on
both subsets of samples.
Results
Univariate Heritability Analyses of TS and OCD
Analysis of the control datasets split by platform demonstrated
no artifactual ‘‘cross-platform’’ heritability (h2 = 0.000001;
se = 0.11, p= 0.5) (Table S2). The overall narrow-sense herita-
bility for TS calculated using the directly genotyped data of 617
TS cases and 4,116 controls was 0.58 (se = 0.09, p = 5.64e-12) and
for OCD (1,061 cases, 4,236 controls) was 0.37(se = 0.07, p = 1.5e-
07) (Table 1). In order to test for possible inflation in the TS
heritability point estimate due to small sample size, the OCD
analysis was repeated using a random set of 617 OCD cases that
matched the TS sample size. This experiment yielded a near-
identical heritability point estimate for OCD with an expected
Genetic Architecture of TS and OCD
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increase in the standard error (h2 = 0.36; se = 0.12, p = 0.0009).
For each primary analysis, ten permutations of the phenotype
were conducted as an additional control, yielding on average no
significant heritability (h2TS = 0.06, se = 0.07, p = 0.3;
h2OCD=0.06, se = 0.08, p = 0.3). Analyses were also conducted
on imputed data, resulting in similar estimates of heritability for
TS (0.48, se = 0.09, p= 3.0e-08) and OCD (0.32, se = 0.07, p= 7e-
06).
Genetic Correlation between TS and OCD
A bivariate analysis of the TS and OCD samples using directly
genotyped data yielded similar estimates for the heritability of TS
(0.51, se = 0.10) and OCD (0.43, se = 0.08). The genetic correla-
tion between the two disorders was 0.41 (se = 0.15), which was
significantly different from zero (LRT=7.98; p = 0.002). We
conducted an exploratory bivariate analysis which limited the
included SNPs to eQTLs identified in parietal cortex or
cerebellum and found a genetic correlation of 0.31 (se = 0.17)
which was also significantly different from zero (LRT=3.62,
p = 0.03). Our assessment of the impact of overlapping phenotypic
co-morbidity on the estimate of genetic correlation resulted in a
smaller, yet purer set of samples (after removing 316 samples with
known TS/tic and OCD co-morbidity) and yielded a genetic
correlation of 0.50 (se = 0.29; LRT=4.08; p = 0.02).
Partitioned Analysis by Chromosome
For both the TS and OCD phenotypes, the summed total of
individual ‘‘by chromosome’’ heritability estimates (h2TS = 0.61,
h2OCD=0.35) were not different than the global univariate
heritability estimates (h2TS = 0.58, h
2
OCD= 0.37) (Table S5 and
S6). These results suggest that population stratification was
appropriately controlled in these analyses.
In addition, there was a significant correlation between both
chromosome length and heritability (r = 0.46, p= 0.03), and
number of genes per chromosome and heritability (r = 0.61,
p = 0.002) in the TS data (Figure 1). The correlations detected
between heritability and chromosome length (r = 0.35, p= 0.11) or
between number of genes and heritability (r = 0.38, p= 0.08) for
OCD did not reach statistical significance (Figure 2).
To test individual chromosomes for any significant concentra-
tion of heritability beyond that expected by chromosome length,
SNP number, or gene number, we calculated the expected
proportion of heritability for each chromosome based on the
number of SNPs (in our data) as well as the number of genes (from
SangerVega) on each chromosome, assuming a polygenic model
with a uniform distribution of heritability across the genome. A
comparative plot of observed ‘‘by chromosome’’ heritability
relative to the expected heritability under the uniform distribution
model demonstrated that chromosome 15 harbored a larger
proportion of heritability for OCD than expected based on either
the number of SNPs or number of genes represented on the
chromosome (Figures S5 and S6). When chromosome 15 was
removed, a significant correlation between chromosome length
and heritability was recovered (r = 0.44, p = 0.05). Greater than
expected heritability per chromosome was discovered in the TS
data for chromosomes 2, 5, 11, 16 and 20 (Figures S7 and S8).
In addition, some chromosomes contributed less heritability to
OCD than expected due to chromosome length alone. Notably
chromosome 6, which houses the HLA locus, did not contribute to
overall heritability estimates in OCD or TS.
Analysis by Minor Allele Frequency (MAF)
We identified a significant difference between TS and OCD in
the proportion of heritability accounted for by variants with
MAF,0.05 (Table 2, Figure 3). This result was observed in
both the directly genotyped data and imputed data. Using the
directly genotyped data, TS SNPs with MAF,0.05 (N= 20,316;
5.3% of all directly genotyped SNPs) represented 21% (0.13,
se = 0.04) of the total calculated heritability, while OCD SNPs
with MAF,0.05 (N=19,605; 5.2% of all directly genotyped
SNPs) represented 0% (0.000001, se = 0.01) of the total calculated
heritability. Similar results were observed using the imputed data,
with approximately 30% of the total heritability of TS captured by
variants with MAF,0.05 (N= 2,243,744; 30% of all imputed
SNPs) and 0% of the total heritability of OCD captured by
variants with MAF,0.05 (2,357,568; 30% of all imputed SNPs).
Analysis by Annotation Classification
In the analysis of directly genotyped data, we found that genic
variants accounted for 53% (0.30, se = 0.07; p = 0.008) of the total
TS heritability and 40% (h2 = 0.15, se = 0.06, p = 0.003) of the
total OCD heritability (Table S7). In the analysis of imputed
Table 1. Overall heritability analysis of obsessive-compulsive disorder and Tourette syndrome.
Diagnosis
Number of
Cases
Number of
Controls
Total Number of
Individuals
Number of
SNPs
Heritability
Estimate (se) p-value
TS 617 4,116 4,733 393,387 0.58 (0.09) 5.64e-12
TS Imputation 617 4,116 4,733 7,782,687 0.48 (0.09) 3.0e-08
OCD 1,061 4,236 5,297 373,846 0.37 (0.07) 1.5e-07
Childhood Onset OCD (#16 yrs old)732 3,985 4,717 373,846 0.43 (0.10) 1e-05
Adult Onset (.16 yrs old) 267 4,200 4,467 373,846 0.26 (0.24) 0.1
OCD** 617 4,355 4,972 373,846 0.36 (0.12) 0.0009
OCD Imputation 1,061 4,236 5,297 7,850,541 0.32 (0.07) 7e-06
Control-Control 1,166 2,457 3,294 392,120 0.0000001 (0.06) 0.5
TS Permutations* 617 4,116 4,733 393,387 0.06 (0.07) 0.3
OCD Permutations* 1,061 4,236 5,297 373,846 0.06 (0.08) 0.3
Legend: se: standard error; SNPs: single nucleotide polymorphisms; TS: Tourette syndrome; OCD: Obsessive-compulsive disorder;
*Average of 10 analyses of permuted phenotypes.
**Sample size reduced to match size of TS sample.
doi:10.1371/journal.pgen.1003864.t001
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data, parietal lobe eQTLs accounted for 28% (h2= 0.13, se = 0.08;
p = 0.03) of the total TS heritability and 29% (h2 = 0.09, se = 0.06;
p = 0.1) of the total OCD heritability. Cerebellar eQTLs
accounted for 35% (h2= 0.11, se = 0.06; p = 0.02) of the total
OCD heritability but only 19% (h2= 0.09, se = 0.07; p = 0.1) of the
total TS heritability (Table 3). When the brain eQTLs were
further subdivided into parietal ‘‘only’’, cerebellum ‘‘only’’ and
those present in parietal lobe and cerebellum we found that,25%
of both TS and OCD heritability was accounted for by parietal
eQTLs, ,10% of both TS and OCD heritability was accounted
for by eQTLs found in both tissues, and that cerebellar eQTLs
again accounted for more heritability (20%) in OCD than in TS
(9%) (Table S8, Figure S9). We then tested a final model in
which brain eQTLs from cerebellum and parietal tissues were
combined into a single ‘‘brain-only’’ partition, and included in the
same joint analysis with muscle eQTLs, eQTL found in both brain
and muscle, and a non-eQTL partition. In this model, brain
eQTLs accounted for 33% (h2 = 0.16, se = 0.10, p= 0.06) of the
total TS heritability and 59% (h2 = 0.19, se = 0.08, p= 0.009) of
the total heritability for OCD. Skeletal muscle eQTLs accounted
for 25% (h2= 0.12; se = 0.10; p = 0.1) of the total TS heritability
and 25% (h2= 0.08; se = 0.09; p = 0.2) of the total heritability for
OCD. The overlapping set of eQTLs identified in both muscle
and brain accounted for 8% heritability in TS (h2= 0.04;
Figure 1. Tourette Syndrome heritability by chromosome. Heritability (y-axis) per chromosome is plotted against chromosome length (x-axis).
The red line represents heritability regressed on chromosome length and the 95% confidence interval around the slope of the regression model is
represented by the red dashed lines. The black line represents the expected heritability per chromosome (based on size) regressed on chromosome
length. Chromosomes 2, 5, 11, 12, 16, and 20 fall outside of the 95% confidence interval and appear to account for more heritability than expected
based on chromosome length.
doi:10.1371/journal.pgen.1003864.g001
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se = 0.08; p= 0.3) and 0% (h2 = 0.0000001; se = 0.06; p= 0.5) of
total OCD heritability. Finally, the remaining non-eQTL portion
of SNPs accounted for only 34% (h2 = 0.16; se = 0.16; p= 0.2) of
TS heritability and 16% (h2 = 0.05; se = 0.08; p = 0.3) of OCD
heritability (Table S9, Figure S10).
Age of Onset (OCD only)
It has been observed that early-onset OCD is more heritable
(h2 = 45–65%) than adult-onset OCD (h2 = 27–47%) [16,46]. To
test this hypothesis in our data, the OCD sample was divided by
age of diagnosis into early-onset (,16 years), yielding 732 case
samples with early-onset OCD, and 267 case samples with adult-
onset OCD. The heritability for early-onset OCD was 0.43
(se = 0.10) and for adult-onset was 0.26 (se = 0.24)(Table 1).
Discussion
GCTA has now been applied to a number of complex traits,
including TS and OCD (Table S10). Results from all of these
analyses show that common interrogated variants account for a
significant proportion of heritability estimated from twin and
family studies [4–8,48]. Depending on the phenotype and original
Figure 2. Obsessive-compulsive disorder heritability by chromosome. Heritability (y-axis) per chromosome is plotted against chromosome
length (x-axis). The red line represents heritability regressed on chromosome length and the 95% confidence interval around the slope of the
regression model is represented by the red dashed lines. The black line represents the expected heritability per chromosome (based on size)
regressed on chromosome length. Chromosome 15 is shown in red to highlight its extreme deviation from the expected heritability based on
chromosome length. Chromosomes 3, 10, 13, and 17 are also outside of the 95% interval and appear to account for more heritability than expected
based on chromosome length.
doi:10.1371/journal.pgen.1003864.g002
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literature estimates, the proportion of heritability explained by
common variation varies across different disorders from essentially
all estimated heritability, as observed in autism, multiple sclerosis
and von Willebrand’s factor, to roughly half of the estimated
heritability, as observed in height, schizophrenia, and type 1
diabetes. This study represents the first effort to use genome-wide
genotype data to determine the heritability of two related
neuropsychiatric disorders, OCD and TS. The narrow-sense
heritability of each disorder (h2GCTA= 0.58 for TS and 0.37 for
OCD) correspond well with previously reported heritability
estimates from family and twin studies [17], [19], [20], [21,22],
[23–25], [26], [27], [28], [29,49] suggesting that there is little, if
any, heritability ‘‘missing’’ (i.e., unassayed). While previous TS
and OCD GWAS have been underpowered to identify individual
susceptibility variants with modest effect sizes, based on these
results, future GWAS in much larger samples should identify a
large number of true TS and OCD disease variants.
The difference between the heritability estimates calculated
from imputed and directly genotyped data was not significant.
However, the imputed heritability estimates were slightly but
Figure 3. Heritability by minor allele frequency. The x-axis represents all minor allele frequency bins tested while the y-axis represents resultant
heritability in a given bin. Blue bars indicate TS and red bars indicate OCD. Error bars are shown.
doi:10.1371/journal.pgen.1003864.g003
Table 2. GWAS and imputed heritability partitioned by minor allele frequency.
Genomic Data
Source MAF Tourette syndrome Obsessive-compulsive disorder
Number of SNPs
(% of total)
Heritability
(se)
%
Heritability
Number of SNPs
(% of total)
Heritability
(se)
%
Heritability
GWAS .0.001–0.05 20,316 (5.1) 0.13 (0.04) 21% 19,605 (5.2) 0.000001 (0.03) 0%
.0.05–0.10 49,445 (12.5) 0.02 (0.05) 3% 47,976 (12.8) 0.04 (0.05) 11%
.0.10–0.20 96,398 (24.5) 0.11 (0.07) 18% 91,661 (24.5) 0.08 (0.06) 23%
.0.20–0.30 81,924 (20.8) 0.12 (0.07) 20% 77,641 (20.7) 0.01 (0.06) 3%
.0.30–0.40 74,393 (18.9) 0.16 (0.07) 26% 70,193 (18.7) 0.11 (0.05) 31%
.0.40–0.50 70,911 (18.0) 0.07 (0.06) 11% 66,770 (17.8) 0.11 (0.05) 31%
Imputed .0.001–0.05 2,243,744 (28.8) 0.15 (0.09) 31% 2,357,568 (30.0) 0.000001 (0.06) 0%
.0.05–0.50 5,538,943 (71.2) 0.34 (0.10) 69% 5,492,973 (70.0) 0.32 (0.12) 100%
Legend: MAF: minor allele frequency; GWAS: genome-wide association study; se: standard error; SNPs: single nucleotide polymorphisms.
doi:10.1371/journal.pgen.1003864.t002
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consistently lower compared to the estimates generated from the
directly genotyped data. While we employed strict r2 thresholds,
the dosage format of imputed data prevented it from being
subjected to the same strict Hardy-Weinberg thresholds as the
directly genotyped data. Therefore this small decrease in measured
heritability may reflect additional noise in the imputed data
contributed by lower quality SNPs. Alternatively, the decrease
may reflect the possibility that even with very stringent QC some
minor residual technical artifacts may have remained in the
directly genotyped data. Perhaps most interesting though, is the
observation that the imputed data did not show a significant
increase in heritability, even with a substantial increase in the
number of interrogated variants, suggesting that the directly
genotyped data alone sufficiently captured the narrow-sense
heritability present in SNP level data.
We identified a significant genetic correlation between TS and
OCD of 0.41 (se = 0.15). This estimate of genetic overlap is smaller
than that observed for schizophrenia/bipolar disorder
(0.6860.04), but similar to that of bipolar disorder/major
depressive disorder (0.4760.06) and schizophrenia/major depres-
sive disorder (0.4360.06) [50]. While this result suggests there is
some degree of shared heritability between the two disorders, the
standard error of the genetic correlation was large. In addition, the
presence of overlapping co-morbidity between TS and OCD in
both samples (13% co-morbid TS or tics in the OCD sample, 43%
co-morbid OCD in the TS sample) may have inflated the
correlation further. After removing all TS and OCD cases with
documented co-morbid OCD or TS, respectively, the subsequent
cleaner, but underpowered analysis yielded a genetic correlation of
0.50 (se = 0.29) which is very similar to the initial correlation of
r = 0.41. It is important to note, however, that some cases with
missing co-morbidity data may have contributed residual co-
morbidity to this sensitivity analysis. Therefore, the bivariate
genetic correlation may still be an overestimate, and should be
interpreted with caution.
We went on to examine the genomic distribution of liability by
partitioning the heritability by chromosome. We found that the
additive heritability estimated by chromosome for either OCD or
TS was not significantly different from the cumulative univariate
heritability calculated by using all data together. This served as an
additional quality control check and confirmed the absence of
residual LD between chromosomes, which can arise in a sample
with cryptic relatedness or population substructure [51]. We
examined the relationship between chromosome length and
proportion of heritability detected, which also provides insight
into the distribution of risk alleles throughout the genome and
helps to characterize the polygenic contribution to risk. We found
evidence, in both TS and OCD, of a highly polygenic architecture,
as demonstrated by the significant correlation between chromo-
somal length and heritability. In addition, the observation that
individual chromosomes in both phenotypes contributed to
heritability disproportionately suggest these chromosomes may
harbor loci with larger effect sizes on a polygenic background of
small effect susceptibility variants distributed equally throughout
the genome.
The initial correlation between OCD heritability and chromo-
some length increased substantially after removal of chromosome
15 (Tables S5 and S6). This increase in correlation is quite
similar to the increase in the correlation between chromosome
length and heritability reported for multiple sclerosis (MS) [48]
upon removal of chromosome 6 (r = 0.45), suggesting that
chromosome 15 may contribute to the heritability of OCD much
to the same degree that chromosome 6 contributes to the
heritability of MS [48]. Regions of chromosome 15 have been
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identified as linkage signals for OCD across multiple populations
[52], [53]. Additionally, genes within the imprinted genomic
region chr15q11-13 have been reproducibly associated with
repetitive behaviors, obsessive compulsive behaviors, and autism
[54], [55], [56], [57]. Together these findings continue to
implicate chromosome 15 in the development of OCD.
Of note, essentially no heritability for either OCD or TS was
observed on chromosome 6, which encodes both the HLA and
histone gene clusters. This absence of heritability within the MHC
region is relevant to these two phenotypes, since an autoimmune
etiology for both OCD and TS has been proposed, based on
similarities between these two disorders and the acute neuropsy-
chiatric presentation of patients with Sydenham chorea in the
setting of acute rheumatic fever and triggered by Group A
streptococcal infection [58]. While an immune-mediated mecha-
nism could still arise from genetic loci outside of the HLA locus,
our result is in stark contrast to schizophrenia, where the strongest
GWAS signal is observed in HLA, suggesting this disorder has an
immune-mediated component [59].
In an effort to further understand the genomic architecture of
OCD and TS, we performed exploratory analyses of heritability
across the MAF spectrum. By running all MAF bins together in a
single REML analysis, we partitioned the effects of LD across each
bin, as Lee et al (2012) previously demonstrated through
simulation that this approach restricts the effects of LD between
bins and reflects expected heritability per bin based on simulated
risk allele distributions. For OCD, no heritability was captured by
SNPs with MAF,5%, while the majority of the heritability
detected was due to those SNPs with MAF.30%. In contrast, for
TS, 21% of the total heritability was captured by SNPs with MAF
less than 5% with the remaining bulk of the heritability shared
approximately equally among alleles with MAF between 0.10–
0.50. Analysis of imputed data confirmed these findings and
showed that SNPs with MAF,0.05 accounted for 30% of the total
TS heritability and 0% of the total OCD heritability. To ensure
that the difference between TS and OCD rare SNP heritability
estimates were not due to subtle population substructure in the TS
sample, we conducted an additional analysis which further
partitioned the MAF,5% bin by chromosome. We then
compared the estimate of heritability calculated by summing each
chromosome (h2= 12.3, se = 0.08) to the estimate of heritability
based on all MAF,5% SNPs in a single analysis (h2 = 12.7,
se = 0.04) and found no significant difference. If population
substructure was present in the TS sample and was a source of
bias contributing to the increased heritability identified in the rare
bin, we would have expected to see inflation of the heritability
estimate due to LD between chromosomes when partitioned by
chromosome and then summed [51]. We can therefore reject the
hypothesis that the rare variant heritability in TS is due to
population substructure.
The observation that TS and OCD have such different patterns
for heritability estimated across the MAF spectrum points to the
value that such analyses may provide for illuminating genetic
architecture. There is clearly support for analysis of rare variants
and follow-up sequencing in TS given the contribution to
heritability observed for SNPs with MAF,0.05. The observations
in OCD are also intriguing with respect to questions on the set of
genetic models that would be consistent with heritability being
concentrated among variants with high MAF. Are such patterns
consistent with particular models for the age of a disorder, or
perhaps with aspects of the evolutionary history of contributing
risk alleles? It will also be important to investigate whether such
analyses applied to other disorders will reveal a full continuum
with respect to the proportion of phenotypic variance attributable
to variants across the MAF spectrum or something more discrete
with overall patterns more similar to OCD at one end and TS at
the other. Replication analysis with larger samples and additional
phenotypes will undoubtedly shed more light on the analysis
presented here.
We partitioned SNPs annotated as brain (parietal and
cerebellum) and muscle eQTLs in an effort to concentrate
heritability within smaller putatively functional classes of testable
variants [60]. Taken together, these results suggest a substantial
contribution to overall heritability by SNPs annotated as brain
eQTLs for both TS and OCD. However, it is important to note
that several limitations of experimental power, including power to
detect eQTLs across tissues, and power to estimate heritability
within our samples, resulted in large standard errors. Cautious
interpretation of these exploratory analyses finds that the ‘‘brain-
only’’ eQTL partition in OCD provides the only statistically
significant estimate of heritability (h2 = 0.19, se = 0.08, p= 0.009)
in a joint analysis with an additional non-brain tissue (muscle),
although the TS ‘‘brain-only’’ partition approaches significance
(h2 = 0.16, se = 0.10, p = 0.06) (Table S9; Figure S8). The result is
intriguing especially considering that the non-eQTL partition
contained over 6.5 million SNPs, approximately twelve times the
number of SNPs contained in the brain-only eQTL partition.
These findings are preliminary and will require replication.
Nevertheless, when interpreted in the context of additional recent
studies showing specific enrichment of brain eQTLs in top GWAS
signals from neuropsychiatric phenotypes, our results suggest that
further study of the role of brain eQTLs in TS and OCD is
warranted [61], [38].
Our results examining the heritability of childhood-onset OCD
are in line with previous studies that suggest a higher heritability
for childhood-onset OCD than for adult onset OCD. However,
because of the smaller sample sizes due to splitting the OCD
sample into two groups based on age of onset, the 95% confidence
intervals for childhood-onset and adult-onset OCD overlap, and
are not significantly different from each other. With increased
sample sizes it may be possible to confirm these observed
heritability differences and to obtain more precise estimates of
the relative heritability of child and adult onset OCD.
Our results explain essentially all of the heritability of TS and a
majority of the heritability of OCD established by twin and family
studies. One factor that may have contributed to the significant
proportion of heritability explained by our results is the
ascertainment strategy employed to collect the samples. As Klei
and colleagues (2012) elegantly demonstrated, heritability estimat-
ed from samples belonging to multiplex families can be greater
than those generated by samples belonging to simplex families.
This phenomenon is most likely a matter of increased polygenic
load reflected in the multiplex samples, as opposed to differing
allelic architectures [6]. Approximately 30% of the TS cases used
in this analysis came from families with more than one affected
individual. Replication of these results in other samples and
populations will be needed to further confirm the heritability
estimates and partition estimates presented here.
In conclusion, this study provides substantial evidence that both
TS and OCD are highly heritable, polygenic, and that a significant
majority of the heritability of both disorders is captured by GWAS
SNP variants. Using both directly genotyped and imputed data, we
also provide evidence of allelic architecture differences between TS
and OCD. Specifically, we identified a significant contribution from
rare variants in the genomic architecture of TS that appears to be
absent from the architecture of OCD. Our results also provide
additional evidence of a prominent role for chromosome 15 in OCD
liability and possible concentration of TS liability on chromosomes 2,
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5, 11, 12, 16 and 20. We also find that brain eQTLs concentrate a
significant proportion of the heritability present in TS andOCD. It is
unlikely that the differences in genetic architecture between TS and
OCD are due to incomplete matching during QC or other,
unknown, technical biases, as all cases were genotyped with identical
technology, shared the same control set, and were imputed together.
Taken together, these results advance our understanding of the
overlapping and non-overlapping genomic architectures of TS and
OCD and suggest that non-overlapping elements of the architecture
of each phenotype may be a limiting factor in the genetic relationship
between them. Moreover, these results may be used to inform
priorities for future studies of both disorders. For example, given the
apparent contribution of rare variants to the heritability of TS, DNA
sequencing may be a particularly informative analysis, whereas
larger sample sizes and additional GWAS is likely to identify the
majority of susceptibility variants for both disorders. Future studies
aimed at understanding the genetic control of shared neurocircuitry
in TS andOCDmay bemost well powered by testing the association
of shared genetic risk (i.e., common polygenic brain eQTLs) with a
well-defined quantitative neurobiological endophenotype. Studies
such as the one presented here continue to highlight the value of ‘‘big
picture’’ analyses, which provide insight into the genetic landscape of
a phenotype, as a necessary and intelligent complement to the
mapping of specific risk variants.
Supporting Information
Figure S1 Q-Q plot of the distribution of p-values for all directly
genotyped SNPs in the ‘‘control-control’’ logistic regression
analysis in which platform was substituted for phenotype. The
top 5 principal components were used as covariates in the analysis.
We observed no deviation from the expected distribution under
the null hypothesis of no association.
(JPG)
Figure S2 The distribution of pi-hat (empirical estimates of
relatedness) among TS cases. A pi-hat threshold of 0.05 was
implemented for all analyses.
(JPG)
Figure S3 The distribution of pi-hat (empirical estimates of
relatedness) among OCD cases. A pi-hat threshold of 0.05 was
implemented for all analyses.
(JPG)
Figure S4 The distribution of pi-hat (empirical estimates of
relatedness) among controls. A pi-hat threshold of 0.05 was
implemented for all analyses.
(JPG)
Figure S5 The x-axis of Figure 5 shows the difference between
the actual OCD heritability calculated per chromosome and the
expected heritability calculated per chromosome based on the
proportion of genes represented by the given chromosome. Each
grey bar represents a chromosome and the error bars shown
represent the error in the actual heritability estimate. The only
chromosome showing significant deviation from expectation is
chromosome 15.
(PDF)
Figure S6 The x-axis of Figure 6 shows the difference between
the actual OCD heritability calculated per chromosome and the
expected heritability calculated per chromosome based on the
proportion of SNPs represented by the given chromosome. Each
grey bar represents a chromosome and the error bars shown
represent the error in the actual heritability estimate. The only
chromosome showing significant deviation from expectation is
chromosome 15.
(PDF)
Figure S7 The x-axis of Figure 7 shows the difference between
the actual TS heritability calculated per chromosome and the
expected heritability calculated per chromosome based on the
proportion of genes represented by the given chromosome.
(PDF)
Figure S8 The x-axis of Figure 8 shows the difference between
the actual TS heritability calculated per chromosome and the
expected heritability calculated per chromosome based on the
proportion of SNPs represented by the given chromosome. Each
grey bar represents a chromosome and the error bars shown
represent the error in the actual heritability estimate. Chromo-
somes 2, 5, 16 and 20 show increased heritability compared to
expectation based on both proportion of genes and proportion of
SNPs.
(PDF)
Figure S9 Figure displays the eQTL annotation based bins
including 1) a ‘‘parietal-only’’ bin consisting of eQTLs identified in
parietal cortex and not in cerebellum, 2) a ‘‘cerebellum-only’’ bin
consisting of eQTLs identified in cerebellum and not in parietal
cortex, and a ‘‘parietal and cerebellum’’ bin consisting of eQTLs
identified in both cerebellum and parietal cortex. Finally, a non-
eQTL partition was included.
(PDF)
Figure S10 Figure displays the eQTL annotation-based bins
including 1) a ‘‘brain-only’’ bin consisting of eQTLs identified in
parietal cortex or cerebellum and not in muscle, 2) a ‘‘muscle-
only’’ bin consisting of eQTLs identified in muscle and not in
parietal cortex or cerebellum, and a ‘‘brain and muscle’’ bin
consisting of eQTLs identified in muscle and either cerebellum,
parietal cortex, or both. Finally, a non-eQTL partition was
included. The asterisk represents a significant p-value of p = 0.009.
(PDF)
Methods S1 Description of additional methods used in the
quality control of samples and SNPs for GCTA analysis.
Additionally, a brief description of the identification of eQTL.
Finally we provide analytic details of the calculation of heritability
on the sibling recurrence risk scale.
(DOC)
Table S1 Effects of differing pi-hat thresholds on Tourette
Syndrome and OCD heritability estimates. Pi-hat refers to the
proportion of alleles shared IBD and thus represents a relatedness
threshold required for each analysis.
(DOC)
Table S2 Control-control analysis with differing QC thresholds.
Table showing changes to the control-control heritability estimate
based on differing filtering approaches to the data. Numbers in each
cell represent the number of SNPs filtered based on each threshold.
MAF=minor allele frequency. Diff SNP Missing= genotypic
differential missingness rate. HWD=SNPs with significant devia-
tion (p,0.05) from Hardy Weinberg Equilibrium. SNP Call
Rate =Genotyping call rate per sample. Platform Effect
SNP=SNPs with significant platform effects. Total# SNPs=Total
number of SNPs surviving QC and used in heritability analysis.
Total# Sample=Total number of subjects surviving QC and used
in heritability analysis. Heritability (se) =Heritability point estimate
and standard error of the estimate. P-value= likelihood ration test
generated p-value for significance of heritability estimate.
(DOC)
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Table S3 Heritability for Tourette syndrome, obsessive-com-
pulsive disorder, and early onset obsessive-compulsive disorder at
a range of reported population prevalence rates.
(DOC)
Table S4 Heritability in terms of sibling recurrence risk (l) for
Tourette syndrome, obsessive-compulsive disorder, and early onset
obsessive-compulsive disorder at a range of population prevalenc-
es. The title l1st-GCTA refers to the risk to first degree relatives
calculated from the given population prevalence and GCTA based
heritability estimate. The title l1st-lit refers to the risk to first degree
relatives calculated from the given population prevalence and the
heritability estimates from the literature cited in the main text of
the paper.
(DOC)
Table S5 Tourette Syndrome heritability partitioned by chro-
mosome. Heritability estimates given for each chromosome for
both directly genotyped and imputed data. P-values calculated
with a likelihood ratio test are also included; * indicates p-values
significant after Bonferroni correction.
(DOC)
Table S6 Obsessive-compulsive disorder heritability partitioned
by chromosome. Heritability estimates given for each chromo-
some for both directly genotyped and imputed data. P-values
calculated with a likelihood ratio test are also included; * indicates
p-values significant after Bonferroni correction.
(DOC)
Table S7 GWAS estimated heritability partitioned by genic
regions. Heritability estimates for TS and OCD partitioned based
on genic annotation. ‘‘Genic’’ includes all coding, intronic, 39UTR
and 59UTR SNPs. Intergenic is defined as not otherwise genic.
The number of SNPs (proportion of total SNPs), heritability, and
proportion of total heritability is given for TS and OCD.
(DOC)
Table S8 Partitioning analysis of heritability based on brain
eQTL annotations. Partitions include eQTLs identified in
cerebellum only, in parietal cortex only, in both parietal cortex
and cerebellum, and non-eQTL SNPs.
(DOC)
Table S9 Partitioning analysis of heritability based on brain and
skeletal muscle eQTL annotations. Partitions include eQTLs
identified in brain only, in muscle only, in both brain and muscle,
and non-eQTL SNPs.
(DOC)
Table S10 Proportion heritability and correlation with chromo-
some length for all phenotypes analyzed with GCTA. Table
includes data from representative account of GCTA publications
with respective reference, phenotype studied, proportion of total
twin/family study heritability estimated by GCTA analysis,
correlations reported for heritability by chromosome and chro-
mosome length, adjusted correlation reported for heritability by
chromosome and chromosome length (upon removal of outliers).
(DOC)
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